AIDS-Related Kaposi Sarcoma, Version 2.2019

Restricted access

As treatment of HIV has improved, people living with HIV (PLWH) have experienced a decreased risk of AIDS and AIDS-defining cancers (non-Hodgkin’s lymphoma, Kaposi sarcoma, and cervical cancer), but the risk of Kaposi sarcoma in PLWH is still elevated about 500-fold compared with the general population in the United States. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for AIDS-Related Kaposi Sarcoma provide diagnosis, treatment, and surveillance recommendations for PLWH who develop limited cutaneous Kaposi sarcoma and for those with advanced cutaneous, oral, visceral, or nodal disease.

Discussion Section Writing Committee

  • 1.

    Statistics US HIV.gov; 2018. Available at: https://www.hiv.gov/hiv-basics/overview/data-and-trends/statistics. Accessed August 31, 2018.

  • 2.

    Goedert JJ, Coté TR, Virgo P, . Spectrum of AIDS-associated malignant disorders. Lancet 1998;351:1833–1839.

  • 3.

    Frisch M, Biggar RJ, Engels EA, . Association of cancer with AIDS-related immunosuppression in adults. JAMA 2001;285:1736–1745.

  • 4.

    Detels R, Munoz A, McFarlane G, . Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators. JAMA 1998;280:1497–1503. Available at: https://www.ncbi.nlm.nih.gov/pubmed/9809730.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 5.

    Palella FJ Jr, Delaney KM, Moorman AC, . Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998;338:853–860.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 6.

    Engels EA, Pfeiffer RM, Goedert JJ, . Trends in cancer risk among people with AIDS in the United States 1980-2002. AIDS 2006;20:1645–1654.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 7.

    Engels EA, Biggar RJ, Hall HI, . Cancer risk in people infected with human immunodeficiency virus in the United States. Int J Cancer 2008;123:187–194.

  • 8.

    Patel P, Hanson DL, Sullivan PS, . Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003. Ann Intern Med 2008;148:728–736.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 9.

    Robbins HA, Shiels MS, Pfeiffer RM, . Epidemiologic contributions to recent cancer trends among HIV-infected people in the United States. AIDS 2014;28:881–890.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 10.

    Shiels MS, Pfeiffer RM, Hall HI, . Proportions of Kaposi sarcoma, selected non-Hodgkin lymphomas, and cervical cancer in the United States occurring in persons with AIDS, 1980-2007. JAMA 2011;305:1450–1459.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 11.

    Robbins HA, Pfeiffer RM, Shiels MS, . Excess cancers among HIV-infected people in the United States. J Natl Cancer Inst 2015;107:DJU503.

  • 12.

    Angeletti PC, Zhang L, Wood C The viral etiology of AIDS-associated malignancies. Adv Pharmacol 2008;56:509–557.

  • 13.

    Chaturvedi AK, Madeleine MM, Biggar RJ, . Risk of human papillomavirus-associated cancers among persons with AIDS. J Natl Cancer Inst 2009;101:1120–1130.

  • 14.

    Grulich AE, van Leeuwen MT, Falster MO, . Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 2007;370:59–67.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 15.

    Hernández-Ramírez RU, Shiels MS, Dubrow R, . Cancer risk in HIV-infected people in the USA from 1996 to 2012: a population-based, registry-linkage study. Lancet HIV 2017;4:e495–e504.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 16.

    Meijide H, Pertega S, Rodriguez-Osorio I, . Increased incidence of cancer observed in HIV/HCV-coinfected patients versus HIV-monoinfected, 1993-2014. AIDS 2017. Available at: https://www.ncbi.nlm.nih.gov/pubmed/28328796. Accessed January 14, 2019.

  • 17.

    Tesoriero JM, Gieryic SM, Carrascal A, . Smoking among HIV positive New Yorkers: prevalence, frequency, and opportunities for cessation. AIDS Behav 2010;14:824–835.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 18.

    Helleberg M, Afzal S, Kronborg G, . Mortality attributable to smoking among HIV-1-infected individuals: a nationwide, population-based cohort study. Clin Infect Dis 2013;56:727–734.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 19.

    McGinnis KA, Fultz SL, Skanderson M, . Hepatocellular carcinoma and non-Hodgkin’s lymphoma: the roles of HIV, hepatitis C infection, and alcohol abuse. J Clin Oncol 2006;24:5005–5009.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 20.

    Park LS, Hernández-Ramírez RU, Silverberg MJ, . Prevalence of non-HIV cancer risk factors in persons living with HIV/AIDS: a meta-analysis. AIDS 2016;30:273–291.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 21.

    Rentsch C, Tate JP, Akgün KM, . Alcohol-related diagnoses and all-cause hospitalization among HIV-infected and uninfected patients: a longitudinal analysis of United States veterans from 1997 to 2011. AIDS Behav 2016;20:555–564. Erratum available at: https://link.springer.com/article/10.1007%2Fs10461-015-1072-4.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 22.

    Marks G, Crepaz N, Senterfitt JW, . Meta-analysis of high-risk sexual behavior in persons aware and unaware they are infected with HIV in the United States: implications for HIV prevention programs. J Acquir Immune Defic Syndr 2005;39:446–453.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 23.

    Branson BM, Handsfield HH, Lampe MA, . Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep 2006;55:1–17; quiz CE11–14.

    • PubMed
    • Export Citation
  • 24.

    Chiao EY, Dezube BJ, Krown SE, . Time for oncologists to opt in for routine opt-out HIV testing? JAMA 2010;304:334–339.

  • 25.

    Hwang JP, Granwehr BP, Torres HA, . HIV testing in patients with cancer at the initiation of therapy at a large US comprehensive cancer center. J Oncol Pract 2015;11:384–390.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 26.

    Li J, Thompson TD, Tai E, . Testing for human immunodeficiency virus among cancer survivors under age 65 in the United States. Prev Chronic Dis 2014;11:E200.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 27.

    Care Continuum HIV HIV.gov; 2017. Available at: https://www.hiv.gov/federal-response/policies-issues/hiv-aids-care-continuum. Accessed September 26, 2018.

  • 28.

    Flash CA, Pasalar S, Hemmige V, . Benefits of a routine opt-out HIV testing and linkage to care program for previously diagnosed patients in publicly funded emergency departments in Houston, TX. J Acquir Immune Defic Syndr 2015;69(Suppl 1):S8–S15.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 29.

    Irvine MK, Chamberlin SA, Robbins RS, . Improvements in HIV care engagement and viral load suppression following enrollment in a comprehensive HIV care coordination program. Clin Infect Dis 2015;60:298–310.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 30.

    Kitahata MM, Gange SJ, Abraham AG, . Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med 2009;360:1815–1826.

  • 31.

    El-Sadr WM, Lundgren J, Neaton JD, . CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006;355:2283–2296.

  • 32.

    Hessol NA, Pipkin S, Schwarcz S, . The impact of highly active antiretroviral therapy on non-AIDS-defining cancers among adults with AIDS. Am J Epidemiol 2007;165:1143–1153.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 33.

    Gérard L, Galicier L, Maillard A, . Systemic non-Hodgkin lymphoma in HIV-infected patients with effective suppression of HIV replication: persistent occurrence but improved survival. J Acquir Immune Defic Syndr 2002;30:478–484.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 34.

    Torres HA, Mulanovich V Management of HIV infection in patients with cancer receiving chemotherapy. Clin Infect Dis 2014;59:106–114.

  • 35.

    Buchacz K, Baker RK, Palella FJ, Jr., . AIDS-defining opportunistic illnesses in US patients, 1994-2007: a cohort study. AIDS 2010;24:1549–1559.

  • 36.

    Ledergerber B, Egger M, Erard V, . AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study. JAMA 1999;282:2220–2226.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 37.

    Schwarcz L, Chen MJ, Vittinghoff E, . Declining incidence of AIDS-defining opportunistic illnesses: results from 16 years of population-based AIDS surveillance. AIDS 2013;27:597–605.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 38.

    Djawe K, Buchacz K, Hsu L, . Mortality risk after AIDS-defining opportunistic illness among HIV-infected persons–San Francisco, 1981-2012. J Infect Dis 2015;212:1366–1375.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 39.

    Borg C, Ray-Coquard I, Philip I, . CD4 lymphopenia as a risk factor for febrile neutropenia and early death after cytotoxic chemotherapy in adult patients with cancer. Cancer 2004;101:2675–2680.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 40.

    Dale DC, McCarter GC, Crawford J, . Myelotoxicity and dose intensity of chemotherapy: reporting practices from randomized clinical trials. J Natl Compr Canc Netw 2003;1:440–454.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 41.

    Seropian S, Nadkarni R, Jillella AP, . Neutropenic infections in 100 patients with non-Hodgkin’s lymphoma or Hodgkin’s disease treated with high-dose BEAM chemotherapy and peripheral blood progenitor cell transplant: out-patient treatment is a viable option. Bone Marrow Transplant 1999;23:599–605.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 42.

    Savage DG, Lindenbaum J, Garrett TJ Biphasic pattern of bacterial infection in multiple myeloma. Ann Intern Med 1982;96:47–50.

  • 43.

    Griffiths H, Lea J, Bunch C, . Predictors of infection in chronic lymphocytic leukaemia (CLL). Clin Exp Immunol 1992;89:374–377.

  • 44.

    Bodey GP, Buckley M, Sathe YS, . Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966;64:328–340.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 45.

    Morrison VA Immunosuppression associated with novel chemotherapy agents and monoclonal antibodies. Clin Infect Dis 2014;59(Suppl 5):S360–S364.

  • 46.

    Schimpff SC Empiric antibiotic therapy for granulocytopenic cancer patients. Am J Med 1986;80(5C):13–20.

  • 47.

    Park J, Kim TM, Hwang JH, . Risk factors for febrile neutropenia during chemotherapy for HIV-related lymphoma. J Korean Med Sci 2012;27:1468–1471.

  • 48.

    Sparano JA, Hu X, Wiernik PH, . Opportunistic infection and immunologic function in patients with human immunodeficiency virus-associated non-Hodgkin’s lymphoma treated with chemotherapy. J Natl Cancer Inst 1997;89:301–307.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 49.

    Wang ES, Straus DJ, Teruya-Feldstein J, . Intensive chemotherapy with cyclophosphamide, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC) for human immunodeficiency virus-associated Burkitt lymphoma. Cancer 2003;98:1196–1205.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 50.

    Lee JY, Dhakal I, Casper C, . Risk of cancer among commercially insured HIV-infected adults on antiretroviral therapy. J Cancer Epidemiol 2016;2016:2138259.

  • 51.

    Yarchoan R, Uldrick TS HIV-associated cancers and related diseases. N Engl J Med 2018;378:1029–1041.

  • 52.

    Antman K, Chang Y Kaposi’s sarcoma. N Engl J Med 2000;342:1027–1038.

  • 53.

    Hiatt KM, Nelson AM, Lichy JH, . Classic Kaposi Sarcoma in the United States over the last two decades: a clinicopathologic and molecular study of 438 non-HIV-related Kaposi Sarcoma patients with comparison to HIV-related Kaposi Sarcoma. Mod Pathol 2008;21:572–582.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 54.

    Labo N, Miley W, Benson CA, . Epidemiology of Kaposi’s sarcoma-associated herpesvirus in HIV-1-infected US persons in the era of combination antiretroviral therapy. AIDS 2015;29:1217–1225.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 55.

    Dubrow R, Qin L, Lin H, . Association of CD4+ T-cell count, HIV-1 RNA viral load, and antiretroviral therapy with Kaposi sarcoma risk among HIV-infected persons in the United States and Canada. J Acquir Immune Defic Syndr 2017;75:382–390.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 56.

    Armstrong AW, Lam KH, Chase EP Epidemiology of classic and AIDS-related Kaposi’s sarcoma in the USA: incidence, survival, and geographical distribution from 1975 to 2005. Epidemiol Infect 2013;141:200–206.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 57.

    Nasti G, Talamini R, Antinori A, . AIDS-related Kaposi’s Sarcoma: evaluation of potential new prognostic factors and assessment of the AIDS Clinical Trial Group Staging System in the Haart Era--the Italian Cooperative Group on AIDS and Tumors and the Italian Cohort of Patients Naive From Antiretrovirals. J Clin Oncol 2003;21:2876–2882.

    • Search Google Scholar
    • Export Citation
  • 58.

    Royse KE, El Chaer F, Amirian ES, . Disparities in Kaposi sarcoma incidence and survival in the United States: 2000-2013. PLoS One 2017;12:e0182750

  • 59.

    Amerson E, Woodruff CM, Forrestel A, . Accuracy of clinical suspicion and pathologic diagnosis of Kaposi sarcoma in east Africa. J Acquir Immune Defic Syndr 2016;71:295–301.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 60.

    Forrestel AK, Naujokas A, Martin JN, . Bacillary angiomatosis masquerading as Kaposi’s sarcoma in East Africa. J Int Assoc Provid AIDS Care 2015;14:21–25.

  • 61.

    Ramdial PK, Sing Y, Ramburan A, . Bartonella quintana-induced vulval bacillary angiomatosis. Int J Gynecol Pathol 2012;31:390–394.

  • 62.

    Jones C, Orengo I, Rosen T, . Cutaneous cryptococcosis simulating Kaposi’s sarcoma in the acquired immunodeficiency syndrome. Cutis 1990;45:163–167.

  • 63.

    Polizzotto MN, Uldrick TS, Wyvill KM, . Clinical features and outcomes of patients with symptomatic Kaposi sarcoma herpesvirus (KSHV)-associated inflammation: Prospective characterization of KSHV inflammatory cytokine syndrome (KICS). Clin Infect Dis 2016;62:730–738.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 64.

    Allen CM, Al-Jahdali HH, Irion KL, . Imaging lung manifestations of HIV/AIDS. Ann Thorac Med 2010;5:201–216.

  • 65.

    Gingo MR, Morris A Pathogenesis of HIV and the lung. Curr HIV/AIDS Rep 2013;10:42–50.

  • 66.

    Gottumukkala RV, Romero JM, Riascos RF, . Imaging of the brain in patients with human immunodeficiency virus infection. Top Magn Reson Imaging 2014;23:275–291.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 67.

    Langford TD, Letendre SL, Larrea GJ, Masliah E. Changing patterns in the neuropathogenesis of HIV during the HAART era. Brain Pathol 2003;13:195–210.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 68.

    Brust D, Polis M, Davey R, . Fluorodeoxyglucose imaging in healthy subjects with HIV infection: impact of disease stage and therapy on pattern of nodal activation. AIDS 2006;20:985–993.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 69.

    Scharko AM, Perlman SB, Pyzalski RW, . Whole-body positron emission tomography in patients with HIV-1 infection. Lancet 2003;362:959–961.

  • 70.

    Goshen E, Davidson T, Avigdor A, . PET/CT in the evaluation of lymphoma in patients with HIV-1 with suppressed viral loads. Clin Nucl Med 2008;33:610–614.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 71.

    Krown SE, Metroka C, Wernz JC. Kaposi’s sarcoma in the acquired immune deficiency syndrome: a proposal for uniform evaluation, response, and staging criteria. J Clin Oncol 1989;7:1201–1207.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 72.

    Beatrous SV, Grisoli SB, Riahi RR, . Cutaneous HIV-associated Kaposi sarcoma: a potential setting for management by clinical observation. Dermatol Online J 2017;23.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 73.

    Asiimwe F, Moore D, Were W, . Clinical outcomes of HIV-infected patients with Kaposi’s sarcoma receiving nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy in Uganda. HIV Med 2012;13:166–171.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 74.

    Bower M, Weir J, Francis N, . The effect of HAART in 254 consecutive patients with AIDS-related Kaposi’s sarcoma. AIDS 2009;23:1701–1706.

  • 75.

    Cattelan AM, Calabrò ML, Gasperini P, . Acquired immunodeficiency syndrome-related Kaposi’s sarcoma regression after highly active antiretroviral therapy: biologic correlates of clinical outcome. J Natl Cancer Inst Monogr 2001;28:44–49.

    • Search Google Scholar
    • Export Citation
  • 76.

    Dupont C, Vasseur E, Beauchet A, . Long-term efficacy on Kaposi’s sarcoma of highly active antiretroviral therapy in a cohort of HIV-positive patients. CISIH 92. Centre d’information et de soins de l’immunodéficience humaine. AIDS 2000;14:987–993.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 77.

    Nguyen HQ, Magaret AS, Kitahata MM, . Persistent Kaposi sarcoma in the era of highly active antiretroviral therapy: characterizing the predictors of clinical response. AIDS 2008;22:937–945.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 78.

    Mosam A, Shaik F, Uldrick TS, . A randomized controlled trial of highly active antiretroviral therapy versus highly active antiretroviral therapy and chemotherapy in therapy-naive patients with HIV-associated Kaposi sarcoma in South Africa. J Acquir Immune Defic Syndr 2012;60:150–157.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 79.

    Bower M, Nelson M, Young AM, . Immune reconstitution inflammatory syndrome associated with Kaposi’s sarcoma. J Clin Oncol 2005;23:5224–5228.

  • 80.

    Fernández-Sánchez M, Iglesias MC, Ablanedo-Terrazas Y, . Steroids are a risk factor for Kaposi’s sarcoma-immune reconstitution inflammatory syndrome and mortality in HIV infection. AIDS 2016;30:909–914.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 81.

    Letang E, Almeida JM, Miró JM, . Predictors of immune reconstitution inflammatory syndrome-associated with kaposi sarcoma in mozambique: a prospective study. J Acquir Immune Defic Syndr 2010;53:589–597.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 82.

    Volkow P, Cesarman-Maus G, Garciadiego-Fossas P, . Clinical characteristics, predictors of immune reconstitution inflammatory syndrome and long-term prognosis in patients with Kaposi sarcoma. AIDS Res Ther 2017;14:30

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 83.

    Guo WX, Antakly T AIDS-related Kaposi’s sarcoma: evidence for direct stimulatory effect of glucocorticoid on cell proliferation. Am J Pathol 1995;146:727–734.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 84.

    Volkow PF, Cornejo P, Zinser JW, . Life-threatening exacerbation of Kaposi’s sarcoma after prednisone treatment for immune reconstitution inflammatory syndrome. AIDS 2008;22:663–665.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 85.

    Bodsworth NJ, Bloch M, Bower M, . Phase III vehicle-controlled, multi-centered study of topical alitretinoin gel 0.1% in cutaneous AIDS-related Kaposi’s sarcoma. Am J Clin Dermatol 2001;2:77–87.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 86.

    Walmsley S, Northfelt DW, Melosky B, . Treatment of AIDS-related cutaneous Kaposi’s sarcoma with topical alitretinoin (9-cis-retinoic acid) gel. J Acquir Immune Defic Syndr 1999;22:235–246.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 87.

    Bubna AK Imiquimod - Its role in the treatment of cutaneous malignancies. Indian J Pharmacol 2015;47:354–359.

  • 88.

    Ganjian S, Ourian AJ, Shamtoub G, . Off-label indications for imiquimod. Dermatol Online J 2009;15:4.

  • 89.

    Babel N, Eibl N, Ulrich C, . Development of Kaposi’s sarcoma under sirolimus-based immunosuppression and successful treatment with imiquimod. Transpl Infect Dis 2008;10:59–62.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 90.

    Benomar S, Boutayeb S, Benzekri L, . Kaposi’s sarcoma responding to topical imiquimod 5% cream: a case report. Cases J 2009;2:7092.

  • 91.

    Bernardini B, Faggion D, Calabró L, . Imiquimod for the treatment of classical Kaposi’s sarcoma. Acta Derm Venereol 2010;90:417–418.

  • 92.

    Prinz Vavricka BM, Hofbauer GF, Dummer R, . Topical treatment of cutaneous Kaposi sarcoma with imiquimod 5% in renal-transplant recipients: a clinicopathological observation. Clin Exp Dermatol 2012;37:620–625.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 93.

    Gündüz K, Günay U, Inanir I, . Efficacy of 5% imiquimod cream in a patient with classic Kaposi sarcoma. J Dermatol Case Rep 2012;6:52–53.

  • 94.

    Fairley JL, Denham I, Yoganathan S, . Topical imiquimod 5% as a treatment for localized genital Kaposi’s sarcoma in an HIV-negative man: a case report. Int J STD AIDS 2012;23:907–908.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 95.

    Célestin Schartz NE, Chevret S, Paz C, . Imiquimod 5% cream for treatment of HIV-negative Kaposi’s sarcoma skin lesions: A phase I to II, open-label trial in 17 patients. J Am Acad Dermatol 2008;58:585–591.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 96.

    Rosen T Limited extent AIDS-related cutaneous Kaposi’s sarcoma responsive to imiquimod 5% cream. Int J Dermatol 2006;45:854–856.

  • 97.

    Lebari D, Gohil J, Patnaik L, . Isolated penile Kaposi’s sarcoma in a HIV-positive patient stable on treatment for three years. Int J STD AIDS 2014;25:607–610.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 98.

    Epstein JB, Lozada-Nur F, McLeod WA, . Oral Kaposi’s sarcoma in acquired immunodeficiency syndrome. Review of management and report of the efficacy of intralesional vinblastine. Cancer 1989;64:2424–2430.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 99.

    Epstein JB Treatment of oral Kaposi sarcoma with intralesional vinblastine. Cancer 1993;71:1722–1725.

  • 100.

    Ramírez-Amador V, Esquivel-Pedraza L, Lozada-Nur F, . Intralesional vinblastine vs. 3% sodium tetradecyl sulfate for the treatment of oral Kaposi’s sarcoma. A double blind, randomized clinical trial. Oral Oncol 2002;38:460–467.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 101.

    Flaitz CM, Nichols CM, Hicks MJ Role of intralesional vinblastine administration in treatment of intraoral Kaposi’s sarcoma in AIDS. Eur J Cancer B Oral Oncol 1995;31:280–285.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 102.

    Friedman M, Venkatesan TK, Caldarelli DD Intralesional vinblastine for treating AIDS-associated Kaposi’s sarcoma of the oropharynx and larynx. Ann Otol Rhinol Laryngol 1996;105:272–274.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 103.

    McCormick SU Intralesional vinblastine injections for the treatment of oral Kaposi’s sarcoma: report of 10 patients with 2-year follow-up. J Oral Maxillofac Surg 1996;54:583–587., discussion 588–589.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 104.

    Shimomura S, Kikuchi Y, Oka S, . Local treatment of AIDS-associated bulky Kaposi’s sarcoma in the head and neck region. Auris Nasus Larynx 2000;27:335–338.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 105.

    Boudreaux AA, Smith LL, Cosby CD, . Intralesional vinblastine for cutaneous Kaposi’s sarcoma associated with acquired immunodeficiency syndrome. A clinical trial to evaluate efficacy and discomfort associated with infection. J Am Acad Dermatol 1993;28:61–65.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 106.

    Smith KJ, Skelton HG, Turiansky G, . Hyaluronidase enhances the therapeutic effect of vinblastine in intralesional treatment of Kaposi’s sarcoma. J Am Acad Dermatol 1997;36:239–242.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 107.

    Vassallo C, Carugno A, Derlino F, . Intralesional vinblastine injections for treatment of classic Kaposi sarcoma in diabetic patients. Cutis 2015;95:E28–E34.

    • Search Google Scholar
    • Export Citation
  • 108.

    Sen F, Tambas M, Ciftci R, . Factors affecting progression-free survival in non-HIV-related Kaposi sarcoma. J Dermatolog Treat 2016;27:275–277.

  • 109.

    Schmidt BM, Holmes CM Classic solitary Kaposi sarcoma of the foot in an immunocompetent patient: a case report. Wounds 2016;28:E35–E40.

    • Search Google Scholar
    • Export Citation
  • 110.

    Cecchi R, Troiano M, Ghilardi M, . Kaposi sarcoma of the penis in an HIV-negative patient. J Cutan Med Surg 2011;15:118–120.

  • 111.

    Ozbek MR, Kutlu N A rare case of Kaposi’s sarcoma; hand localization. Handchir Mikrochir Plast Chir 1990;22:107–109.

  • 112.

    Weintraub CM, Skudowitz RB Excision of 1,674 classic Kaposi’s sarcomas. S Afr J Surg 2002;40:80.

  • 113.

    Becker G, Bottke D Radiotherapy in the management of Kaposi’s sarcoma. Onkologie 2006;29:329–333.

  • 114.

    Caccialanza M, Marca S, Piccinno R, . Radiotherapy of classic and human immunodeficiency virus-related Kaposi’s sarcoma: results in 1482 lesions. J Eur Acad Dermatol Venereol 2008;22:297–302.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 115.

    Cooper JS, Steinfeld AD, Lerch I Intentions and outcomes in the radiotherapeutic management of epidemic Kaposi’s sarcoma. Int J Radiat Oncol Biol Phys 1991;20:419–422.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 116.

    Donato V, Guarnaccia R, Dognini J, . Radiation therapy in the treatment of HIV-related Kaposi’s sarcoma. Anticancer Res 2013;33:2153–2157.

  • 117.

    Kirova YM, Belembaogo E, Frikha H, . Radiotherapy in the management of epidemic Kaposi’s sarcoma: a retrospective study of 643 cases. Radiother Oncol 1998;46:19–22.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 118.

    Nobler MP, Leddy ME, Huh SH The impact of palliative irradiation on the management of patients with acquired immune deficiency syndrome. J Clin Oncol 1987;5:107–112.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 119.

    Singh NB, Lakier RH, Donde B Hypofractionated radiation therapy in the treatment of epidemic Kaposi sarcoma--a prospective randomized trial. Radiother Oncol 2008;88:211–216.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 120.

    Tsao MN, Sinclair E, Assaad D, . Radiation therapy for the treatment of skin Kaposi sarcoma. Ann Palliat Med 2016;5:298–302.

  • 121.

    Wang J, Boerma M, Fu Q, . Radiation responses in skin and connective tissues: effect on wound healing and surgical outcome. Hernia 2006;10:502–506.

  • 122.

    Spałek M Chronic radiation-induced dermatitis: challenges and solutions. Clin Cosmet Investig Dermatol 2016;9:473–482.

  • 123.

    Northfelt DW, Dezube BJ, Thommes JA, . Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi’s sarcoma: results of a randomized phase III clinical trial. J Clin Oncol 1998;16:2445–2451.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 124.

    Stewart S, Jablonowski H, Goebel FD, . Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi’s sarcoma. J Clin Oncol 1998;16:683–691.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 125.

    Armenian SH, Lacchetti C, Barac A, . Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2017;35:893–911.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 126.

    Smith LA, Cornelius VR, Plummer CJ, . Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials. BMC Cancer 2010;10:337.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 127.

    Carver JR, Shapiro CL, Ng A, . American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects. J Clin Oncol 2007;25:3991–4008.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 128.

    DOXIL®(doxorubicin hydrochloride liposome injection), for intravenous use. Horsham, PA: Janssen Products, LP; 2016. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050718s051lbl.pdf. Accessed November 21, 2018.

  • 129.

    Welles L, Saville MW, Lietzau J, . Phase II trial with dose titration of paclitaxel for the therapy of human immunodeficiency virus-associated Kaposi’s sarcoma. J Clin Oncol 1998;16:1112–1121.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 130.

    Saville MW, Lietzau J, Pluda JM, . Treatment of HIV-associated Kaposi’s sarcoma with paclitaxel. Lancet 1995;346:26–28.

  • 131.

    Cianfrocca M, Lee S, Von Roenn J, . Randomized trial of paclitaxel versus pegylated liposomal doxorubicin for advanced human immunodeficiency virus-associated Kaposi sarcoma: evidence of symptom palliation from chemotherapy. Cancer 2010;116:3969–3977.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 132.

    Gbabe OF, Okwundu CI, Dedicoat M, Freeman EE. Treatment of severe or progressive Kaposi’s sarcoma in HIV-infected adults. Cochrane Database Syst Rev 2014;CD003256. Available at: https://www.ncbi.nlm.nih.gov/pubmed/25313415.

    • Search Google Scholar
    • Export Citation
  • 133.

    Northfelt DW, Dezube BJ, Thommes JA, . Efficacy of pegylated-liposomal doxorubicin in the treatment of AIDS-related Kaposi’s sarcoma after failure of standard chemotherapy. J Clin Oncol 1997;15:653–659.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 134.

    Stebbing J, Wildfire A, Portsmouth S, . Paclitaxel for anthracycline-resistant AIDS-related Kaposi’s sarcoma: clinical and angiogenic correlations. Ann Oncol 2003;14:1660–1666.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 135.

    Polizzotto MN, Uldrick TS, Wyvill KM, . Pomalidomide for symptomatic Kaposi’s sarcoma in people with and without HIV infection: a phase I/II study. J Clin Oncol 2016;34:4125–4131.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 136.

    Erratum. J Clin Oncol 2018;36:2008.

  • 137.

    Uldrick TS, Wyvill KM, Kumar P, . Phase II study of bevacizumab in patients with HIV-associated Kaposi’s sarcoma receiving antiretroviral therapy. J Clin Oncol 2012;30:1476–1483.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 138.

    Schwartsmann G, Sprinz E, Kromfield M, . Clinical and pharmacokinetic study of oral etoposide in patients with AIDS-related Kaposi’s sarcoma with no prior exposure to cytotoxic therapy. J Clin Oncol 1997;15:2118–2124.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 139.

    Sprinz E, Caldas AP, Mans DR, . Fractionated doses of oral etoposide in the treatment of patients with aids-related kaposi sarcoma: a clinical and pharmacologic study to improve therapeutic index. Am J Clin Oncol 2001;24:177–184.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 140.

    Evans SR, Krown SE, Testa MA, . Phase II evaluation of low-dose oral etoposide for the treatment of relapsed or progressive AIDS-related Kaposi’s sarcoma: an AIDS Clinical Trials Group clinical study. J Clin Oncol 2002;20:3236–3241.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 141.

    Strother RM, Gregory KM, Pastakia SD, . Retrospective analysis of the efficacy of gemcitabine for previously treated AIDS-associated Kaposi’s sarcoma in western Kenya. Oncology 2010;78:5–11.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 142.

    Busakhala NW, Waako PJ, Strother MR, . Randomized phase IIA trial of gemcitabine compared with bleomycin plus vincristine for treatment of Kaposi’s sarcoma in patients on combination antiretroviral therapy in Western Kenya. J Glob Oncol 2018;4:1–9.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 143.

    Cao W, Vyboh K, Routy B, . Imatinib for highly chemoresistant Kaposi sarcoma in a patient with long-term HIV control: a case report and literature review. Curr Oncol 2015;22:e395–e399.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 144.

    Koon HB, Bubley GJ, Pantanowitz L, . Imatinib-induced regression of AIDS-related Kaposi’s sarcoma. J Clin Oncol 2005;23:982–989.

  • 145.

    Koon HB, Krown SE, Lee JY, . Phase II trial of imatinib in AIDS-associated Kaposi’s sarcoma: AIDS Malignancy Consortium Protocol 042. J Clin Oncol 2014;32:402–408.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 146.

    Opravil M, Hirschel B, Bucher HC, . A randomized trial of interferon-alpha2a and zidovudine versus bleomycin and zidovudine for AIDS-related Kaposi’s sarcoma. Swiss HIV Cohort Study. Int J STD AIDS 1999;10:369–375.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 147.

    Shepherd FA, Beaulieu R, Gelmon K, . Prospective randomized trial of two dose levels of interferon alfa with zidovudine for the treatment of Kaposi’s sarcoma associated with human immunodeficiency virus infection: a Canadian HIV Clinical Trials Network study. J Clin Oncol 1998;16:1736–1742.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 148.

    Miles S, Levine A, Feldstein M, . Open-label phase I study of combination therapy with zidovudine and interferon-beta in patients with AIDS-related Kaposi’s sarcoma: AIDS Clinical Trials Group Protocol 057. Cytokines Cell Mol Ther 1998;4:17–23.

    • Search Google Scholar
    • Export Citation
  • 149.

    Fischl MA, Finkelstein DM, He W, . AIDS Clinical Trials Group A phase II study of recombinant human interferon-alpha 2a and zidovudine in patients with AIDS-related Kaposi’s sarcoma. J Acquir Immune Defic Syndr Hum Retrovirol 1996;11:379–384.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 150.

    Krown SE, Li P, Von Roenn JH, . Efficacy of low-dose interferon with antiretroviral therapy in Kaposi’s sarcoma: a randomized phase II AIDS clinical trials group study. J Interferon Cytokine Res 2002;22:295–303.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 151.

    Krown SE, Lee JY, Lin L, . Interferon-alpha2b with protease inhibitor-based antiretroviral therapy in patients with AIDS-associated Kaposi sarcoma: an AIDS malignancy consortium phase I trial. J Acquir Immune Defic Syndr 2006;41:149–153.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 152.

    Fortino S, Santoro M, Iuliano E, . Treatment of Kaposi's Sarcoma (KS) with nab-paclitaxel. Ann Oncol 2016;27:suppl_4: iv124. Available at: https://doi.org/10.1093/annonc/mdw345.63.

    • Crossref
    • Export Citation
  • 153.

    Little RF, Wyvill KM, Pluda JM, . Activity of thalidomide in AIDS-related Kaposi’s sarcoma. J Clin Oncol 2000;18:2593–2602.

  • 154.

    Fife K, Howard MR, Gracie F, . Activity of thalidomide in AIDS-related Kaposi’s sarcoma and correlation with HHV8 titre. Int J STD AIDS 1998;9:751–755.

  • 155.

    Nasti G, Errante D, Talamini R, . Vinorelbine is an effective and safe drug for AIDS-related Kaposi’s sarcoma: results of a phase II study. J Clin Oncol 2000;18:1550–1557.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 156.

    Dantal J, Soulillou JP Immunosuppressive drugs and the risk of cancer after organ transplantation. N Engl J Med 2005;352:1371–1373.

  • 157.

    Pantanowitz L, Früh K, Marconi S, . Pathology of rituximab-induced Kaposi sarcoma flare. BMC Clin Pathol 2008;8:7

All Time Past Year Past 30 Days
Abstract Views 3 3 0
Full Text Views 1799 1800 80
PDF Downloads 443 443 21
EPUB Downloads 0 0 0